Flow cytometric analysis of FMC63 expression on CAR (FMC63 scFv) transfected T cells (from human PBMCs) (right panel) or T cells (left panel) were stained with SDT Alexa Fluor® 647 Mouse Anti-FMC63 Antibody at 2 μl/test. Total viable cells, as determined by Fixable Viability Dye 452 (S0B88801), were used for analysis. Flow cytometry and data analysis were performed using Agilent NovoCyte Quanteon and FlowJo™ software.
Product Details
Product Details
Product Specification
| Host | Mouse |
| Clone Number | S-5031 |
| Antibody Type | Mouse mAb |
| Isotype | IgG1,k |
| Isotype Control | S0B5964 |
| Application | FCM |
| Reactivity | Species independent |
| Purification | Protein G |
| Concentration | 0.1 mg/ml |
| Conjugation | Alexa Fluor® 647 |
| Physical Appearance | Liquid |
| Storage Buffer | PBS, 1% BSA, 0.09% sodium azide |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| FCM | 2μl per million cells in 100μl volume | Species independent |
Background
FMC63 scFv (single-chain variable fragment) is a recombinant protein derived from the variable regions (VH and VL) of the anti-CD19 monoclonal antibody FMC63, linked by a flexible peptide spacer (e.g., (Gly₄Ser)₃). It specifically binds to the B-cell surface antigen CD19 with high affinity (KD ~1-10 nM) and is a key targeting component in FDA-approved CAR-T therapies, such as Kymriah®. The humanized FMC63 scFv retains potent antigen recognition while minimizing immunogenicity, making it highly effective in treating B-cell malignancies, including acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). Ongoing research focuses on optimizing its affinity, stability, and functionality to enhance the safety and efficacy of CAR-T cell therapies.
Picture
Picture
FC
